March 25, 2022
Nobelpharma Co., Ltd.

“LUNABELL® Combination Tablet LD/ULD”
Addition of "indication" and "dosage and administration" for fertility treatment

Nobelpharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Managing Director & CEO: Jin Shiomura), announced today that the additional approval for LUNABELL® Combination Tablet LD/ULD (generic name: norethisterone/ethinylestradiol), which has been sold through Nippon Shinyaku Co., Ltd. (Kyoto City, President Toru Nakai) and Fuji Pharma Co., Ltd. (Tokyo, President and CEO Takayuki Iwai), has been obtained as described below on March 11, 2022.

The efficacy and safety of this drug for "adjusting the timing of initiation of regulated ovarian stimulation in assisted reproductive technology" have been evaluated as the medical and pharmaceutical public knowledge based on the findings of a domestic usage survey and domestic and foreign clinical practice guidelines.

With this approval of the additional indication, we are pleased that the drug will be a new option for assisted reproductive technology in fertility treatment.

We will continue to contribute to society by providing critical but neglected pharmaceuticals and medical devices.

Extract of the Additional “Indication” and “Dosage and Administration”*

“Indication”

○Coordinating the Timing of Initiation of Modulated Ovarian Stimulation in Assisted Reproductive Technology

“Dosage and Administration”

Take 1 tablet a day orally at a fixed time, in general for 14-21 days.

*The coverage of this additional "Indications" and "Dosage and Administration" of this drug will begin in April 2022.

[Contact for inquiries regarding this matter]
Nobelpharma Co., Ltd.
Noboru Kudo
Head of Communications
1-17-24, Shinkawa, Chuo-ku, Tokyo 104-0033
Tel: 03-6670-3800